Personalized Therapy in Gynecological Cancer: A Reality in Clinical Practice?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Personalised medicine has already transformed oncology practice for a number of cancers. The rationale for molecularly targeted therapies is that such agents are more selective and therefore hold the promise of greater efficacy and potentially lower toxicity than conventional chemotherapy. Trastuzumab, a monoclonal antibody against the HER2 receptor, revolutionized the management of HER2-positive (overexpression and/or gene amplification) breast cancer (15–20 % of all cases) and has had a major impact on survival in a group of patients that otherwise have a more aggressive clinical course. In lung cancer clinics, EGFR mutational status directs the use of EGFR inhibitors (erlotinib and gefitinib) and more recently, the rapid development of the EML4-ALK inhibitor, crizotinib, along with the validation of the companion diagnostic test, has led to the approval of crizotinib. This targeted agent has impressive results in the distinct subset of non-small cell lung cancer patients (approximat ...
- Banerjee S, Kaye SB. New Strategies in the treatment of ovarian cancer -current clinical perspectives and future potential. Clin Canc Res. 2013. Epub 2013/01/12.
- Integrated genomic analyses of ovarian carcinoma. Cancer Genome Atlas Research Network. Nature. 2011;474(7353):609–15. Epub 2011/07/02.
- Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol. 2012;24(5):554–63. Epub 2012/05/15. CrossRef
- Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. Epub 2011/12/30. CrossRef
- Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83. Epub 2011/12/30. CrossRef
- Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–45. Epub 2012/04/25. CrossRef
- Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol. 2012;30(suppl; abstr LBA5002^).
- Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol. 2010;7(9):508–19. Epub 2010/08/12. CrossRef
- Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92. Epub 2012/03/29. CrossRef
- Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134–40. Epub 2012/12/25. CrossRef
- Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012;30(8):777–82. Epub 2012/01/25. CrossRef
- Mackay H, Eisenhauer E, Kamel-Reid S, Clarke B, Walsh W, Karakasis K, et al. Molecular determinants of outcome with mTOR inhibition in endometrial cancer (EC). J Clin Oncol. 2012;30. abstract 5010.
- Personalized Therapy in Gynecological Cancer: A Reality in Clinical Practice?
Current Oncology Reports
Volume 15, Issue 3 , pp 201-203
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Industry Sectors